REPEAT: Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings.
●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process.
●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities.
●
Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related
— more than breast, prostate, lung, and colon cancers combined.
●
22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily
from this serious form of skin cancer.
●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals.
Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) —
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country.
Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform.
'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.'
Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care.
The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it.
'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.'
The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date.
Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025.
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
Visit
www.rocketdoctor.ca
or contact
media@rocketdoctor.io
.
About Melanoma Canada
Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers.
Learn more at
www.melanomanetwork.ca
.
About
Treatment.com
AI Inc.
Treatment.com
AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at
www.treatment.com
or contact
info@treatment.com
.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
Email:
ehamza@treatment.com
Media inquiries:
media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity
By Aditya Bhagchandani Published on August 20, 2025, 10:16 IST Shares of Lupin Ltd. will be in focus on Wednesday, August 20, after the company announced the launch of Bosentan Tablets for Oral Suspension, 32 mg, in the United States. The launch, made in partnership with NATCO Pharma, comes with the advantage of 180-day first-to-file generic exclusivity, a significant opportunity in the niche space of pulmonary arterial hypertension (PAH) treatment. The government filing confirmed that Lupin's alliance partner NATCO Pharma received U.S. FDA approval for its Abbreviated New Drug Application (ANDA). Bosentan is indicated for the treatment of PAH in pediatric patients aged three years and above with idiopathic or congenital PAH, aiming to improve pulmonary vascular resistance and exercise ability. The drug is bioequivalent to Actelion Pharmaceuticals' Tracleer® Tablets for Oral Suspension, which had estimated annual U.S. sales of around USD 10 million as of June 2025. Lupin, a major player in generics and specialty formulations, continues to strengthen its U.S. portfolio with this launch. The company has a strong footprint across therapy areas, including respiratory, cardiovascular, anti-diabetic, and women's health, and operates 15 manufacturing sites and seven research centers globally. With the exclusivity window, Lupin and NATCO are positioned to capture market share in the PAH treatment segment before competition intensifies. Disclaimer: This article is for informational purposes only and should not be considered investment advice. Please consult a financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
5 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Is cereal good or bad for you? 11 best 'healthy' brands in Canada, ranked on sugar, fibre, protein and more
A dietitian says that regardless of healthiness, it's necessary to start your day by fuelling your body with food. If in the mad-dash morning rush you're managing to put any food in your stomach at all, registered dietitian Janine LaForte wants you to know you're doing all right. She knows breakfast is a challenge for those facing the consequences of the snooze button or racing against the arrival of the school bus. This stress, LaForte says, is particularly felt for families facing food insecurity, an interlocking barrier mounting up on top of regular morning hurley-burley. LaForte, who also owns Real Life Nutrition in Winnipeg, notes her personal ideal morning meal isn't breakfast cereal: 'It would be something like just an oatmeal, right? There's that one ingredient [and] you add in what you'd like.' This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. However, she notes that cereal is an affordable, dependable choice to start the day for many: 'There are a lot of families who are struggling. And there's a lot of kids who don't want to eat breakfast. And cereal — and I will tell you, from my own personal experience — has been the go-to breakfast because it's quick. Kids are often rushing in the morning, and parents [are] as well.' Cereal, she says, is typically an easy, quick meal. 'If it's a matter of eating a bowl of cereal, even if it's something that you may deem not so 'healthy,' it's at least something that they're getting in before they go out the door. Or even as an adult goes out the door.' But with some cereals so laden with sugar that they border on candy, how can you make sure you're pouring yourself a bowl of goodness in those snatched A.M. moments? Here, LaForte guides us through what makes some cereals stack up better than others. Plus, keep scrolling for a nutritional comparison of some of the most popular 'healthy' cereal brands you can find in Canadian grocery stores. Fibre, sugar, balance: What to look for when shopping for cereal 'I think breakfast is a really good opportunity to get fibre in your diet,' LaForte says, adding that choosing higher-fibre cereal is an excellent starting point for a nutritious breakfast. Whole grains, of course, pack more fibre than their refined counterparts, so LaForte suggests checking ingredient lists to ensure what your cereal is made of. A 2015 study (the most recent stats available) from the American Journal of Clinical Nutrition shares LaForte's focus on fibre. It indicates that less than 25 per cent of Canadians age 19 and older get enough of the digestion-and-satiety-aiding nutrient daily. Making a bowl of cereal into a balanced meal with staying power also means topping the cereal with things like fruit, seeds, nuts or yogurt, LaForte adds. Think classic options like sliced bananas and blueberries, or even pumpkin seeds and Greek yogurt. She also adds that variety is the key to good nutrition, so switching up the toppings and the cereals themselves — say, trying one made from corn and then one made from wheat — helps ensure you're getting different nutrients into your overall diet. Then there's sugar, an ingredient LaForte says 'people tend to eat more [of] than they need to.' Comparing nutritional labels and going for the lower-sugar option is an effective method to make sure you're pouring a healthier bowl of cereal. But LaForte does note that since cereals are 'fortified with vitamins and minerals in Canada,' the sugary treats could be a source of nutrients for picky eaters and those facing food insecurity. While reducing added sugar where you can in your diet is an important part of healthy eating, so is ensuring that you're getting enough of key nutrients. Are popular 'healthy' cereal brands in Canada actually healthy? In the breakdown below, we've rounded up a variety of healthy cereals to see which ones are your best A.M. bet in terms of nutritional information per a one-cup serving — not including milk. It's worth mentioning that all of the cereals are sources of nutrients like potassium, calcium and iron, with a majority also having several vitamins. It turns out that Shredded Wheat is tough to beat with no sugar and a mere gram of fat alongside a high fibre and protein content. Müslix, meanwhile, packs more sugar and fat than you might expect. Fibre One, on the other hand, lives up to its name with a whopping 27 grams of fibre — just five grams less than an average adult woman needs daily. Shredded Wheat Original Calories: 180 Fat: 1 g Fibre: 6 g Sugar: 0 g Sodium: 0 g Protein: 5 g Fibre One Crunchy Original Calories: 140 Fat: 1 g Fibre: 27 g Sugar: 1 g Sodium: 220 mg Protein: 4 g Multi Grain Cheerios Calories: 120 Fat: 1 g Fibre: 2 g Sugar: 6 g Sodium: 160 mg Protein: 2 g Kellogg's Two Scoops Raisin Bran Calories: 180 Fat: 1 g Fibre: 7 g Sugar: 14 g Sodium: 170 mg Protein: 5 g Nature's Path Smart Bran Calories: 140 Fat: 2 g Fibre: 23 g Sugar: 11 g Sodium: 230 mg Protein: 5 g Nature's Path Multigrain Flakes Calories: 210 Fat: 2 g Fibre: 10 g Sugar: 8 g Sodium: 210 mg Protein: 6 g Kellogg's All-Bran Original Calories: 180 Fat: 3 g Fibre: 18 g Sugar: 10 g Sodium: 320 mg Protein: 8 g Kellogg's Vector Maple Flavour Calories: 160 Fat: 1 g Fibre: 3 g Sugar: 12 g Sodium: 160 mg Protein: 10 g Kashi GoActive Mixed Berry Crunch Calories: 290 Fat: 4.5 g Fibre: 14 g Sugar: 15 g Sodium: 85 mg Protein: 14 g Kashi GoActive Honey Almond Flax Crunch Calories: 300 Fat: 8 g Fibre: 15 g Sugar: 17 g Sodium: 230 mg Protein: 15 g Kellogg's Müslix Almond Raisin Calories: 240 Fat: 2.5 g Fibre: 7 g Sugar: 17 g Sodium: 150 mg Protein: 6 g In the end, no matter if you're eating Shredded Wheat or Coco Puffs, LaForte touts the importance of starting your day with breakfast: 'Food is the fuel for our bodies. If you want to be able to function and do your best during your day, you need to fuel your brain. 'Some people don't like eating breakfast. However, if you can get something in, anything — a yogurt, some fruit, a balanced breakfast is the best. But if you can just get something in within an hour of waking up, that's going to be the best for your body.'
